RespondWell

Zimmer Biomet Holdings Inc. (NYSE: ZBH) has bought RespondWell, a maker of medical technology used for post-surgery recovery at home, as stricter regulations have forced health care providers to focus on improving patient care. Terms of the deal were undisclosed amount.

RespondWell develops telerehabilitation technology for patients undergoing physical therapy. Doctors use so-called "tele-rehabilitation" to communicate with patients online and provide onscreen tools. The target now offers a specific care plan through the Therapy@Home technology, serving as a virtual therapist in a convenient location. The video gaming style exercise system includes on-screen digital coaches to encourage and motivate patient participation. RespondWell co-founder Ted Spooner says "tele-rehabilitation" is the future of post-surgical care.

As part of the deal, the target has joined the Zimmer Biomet Signature Solutions division. The division serves as a portfolio of technologies and services designed to help health providers streamline patient care. The deal for RespondWell’s virtual assistant product is expected to help Zimmer improve post-surgical care, as improving patient results is one factor that has been driving medical technology deals.

New regulations and the "value-based reimbursement environment compels hospitals and providers to assume responsibility for patient outcomes well after discharge and through the critical rehabilitation period," according to Zimmer group president David Nolan.

In August 2016, Zimmer purchased CD Diagnostics, a developer of medical tests designed to advance joint infection treatments. Warsaw, Indiana-based Zimmer, a maker of orthopedic, also bought spine surgery tech developer LDR Holding. Other health care technology deals include: Auris Surgical Robotics Inc. announced plans to purchase medical robot manufacturer Hansen Medical Inc.; MedData Inc. is buying hospital software developer Cardon Outreach; and Thoma Bravo is acquiring medical IT security firm Imprivata (NYSE: IMPR).

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.